Zileuton
(Synonyms: 齐留通; A 64077; Abbott 64077) 目录号 : GC16014
Zileuton是一种苯并噻吩N-羟基脲类化合物，作为口服5-脂氧合酶抑制剂。
Cas No.:111406-87-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Zileuton, a benzothiophene N-hydroxyurea, is an oral inhibitor of 5-Lipoxygenase[1]. Zileuton blocks 5-lipoxygenase activity to regulate leukotriene formation and reduces bronchial smooth-muscle tone[2]. Zileuton is a weak inhibitor of human liver microsomal CYP3A4, CYP2C9, and CYP2D6 activity, with IC50 >100μM [3]. Zileuton has been widely used in animal models to suppress inflammation and improve airway function[4].
In vitro, Zileuton treatment at 0.05μM Zileuton for 14 days reduced the content of neutral lipids and the release of interleukin-6 in human SZ95 sebocytes[5]. Treatment with 100µM Zileuton for 24h inhibited the lipopolysaccharide (LPS)-triggered increase in PGE2 production in mouse J774 macrophages without affecting cell viability[6]. Treatment with 50µM Zileuton for 1 hour significantly inhibited the proliferation and migration of human umbilical vein endothelial cells (HUVEC) induced by vascular endothelial growth factor (VEGF)[7].
In vivo, Zileuton treatment (50mg/kg; twice daily; p.o.) for 7 days alleviated colonic injury and decreased colonic myeloperoxidase (MPO) activity in an experimental model of rat colitis[8]. Oral administration of drinking water containing Zileuton (200mg/L) daily for 3 months can restore the memory impairment in aged mice with Alzheimer's disease and reverse the amyloid protein and tau pathological changes[9]. A single oral dose of Zileuton at 50mg/kg for 72 hours can inhibit neuronal apoptosis in rats after focal cerebral ischemia and alleviate brain damage[10].
References:
[1] Berger W, De Chandt M T M, Cairns C B. Zileuton: clinical implications of 5‐Lipoxygenase inhibition in severe airway disease[J]. International journal of clinical practice, 2007, 61(4): 663-676.
[2] Bell R L, Young P R, Albert D, et al. The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor[J]. International journal of immunopharmacology, 1992, 14(3): 505-510.
[3] Lu P, Schrag M L, Slaughter D E, et al. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor[J]. Drug Metabolism and Disposition, 2003, 31(11): 1352-1360.
[4] Muthukrishnan P T, Nouraie M, Parikh A, et al. Zileuton use and phenotypic features in asthma[J]. Pulmonary Pharmacology & Therapeutics, 2020, 60: 101872.
[5] Zouboulis C C. Zileuton, a new efficient and safe systemic anti-acne drug[J]. Dermato-endocrinology, 2009, 1(3): 188-192.
[6] Rossi A, Pergola C, Koeberle A, et al. The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages[J]. British journal of pharmacology, 2010, 161(3): 555-570.
[7] Lim H J, Park J, Um J Y, et al. Zileuton, a 5-lipoxygenase inhibitor, exerts anti-angiogenic effect by inducing apoptosis of HUVEC via BK channel activation[J]. Cells, 2019, 8(10): 1182.
[8] Zingarelli B, Squadrito F, Graziani P, et al. Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats[J]. Agents and actions, 1993, 39(3): 150-156.
[9] Di Meco A, Lauretti E, Vagnozzi A N, et al. Zileuton restores memory impairments and reverses amyloid and tau pathology in aged Alzheimer's disease mice[J]. Neurobiology of aging, 2014, 35(11): 2458-2464.
[10] Shi S, Yang W, Tu X, et al. 5-Lipoxygenase inhibitor zileuton inhibits neuronal apoptosis following focal cerebral ischemia[J]. Inflammation, 2013, 36(6): 1209-1217.
Zileuton是一种苯并噻吩N-羟基脲类化合物，作为口服5-脂氧合酶抑制剂[1]。Zileuton通过阻断5-脂氧合酶活性调节白三烯合成，降低支气管平滑肌张力[2]。Zileuton对人肝微粒体CYP3A4、CYP2C9和CYP2D6活性抑制较弱（IC50 >100μM）[3]。Zileuton已广泛应用于动物模型的炎症抑制和气道功能改善研究[4]。
在体外，0.05μM的Zileuton处理人SZ95皮脂腺细胞14天可减少中性脂质含量并降低白细胞介素-6释放[5]。100µM的Zileuton处理小鼠J774巨噬细胞24小时能抑制脂多糖（LPS）触发的PGE2产量增加且不影响细胞活力[6]。50µM的Zileuton处理人脐静脉内皮细胞（HUVEC）1小时可显著抑制血管内皮生长因子（VEGF）诱导的增殖与迁移[7]。
在体内，实验性结肠炎大鼠每日两次口服Zileuton（50mg/kg；持续7天）可减轻结肠损伤并降低结肠髓过氧化物酶（MPO）活性[8]。每日口服含Zileuton（200mg/L）的饮用水，连续3个月，可恢复老年阿尔茨海默病小鼠的记忆障碍，逆转淀粉样蛋白和tau的病理改变[9]。单次口服50mg/kg剂量的Zileuton（72小时）可抑制局灶性脑缺血后的大鼠神经元凋亡并减轻大鼠轻脑损伤[10]。
| Cell experiment [1]: | |
Cell lines | Mouse J774 macrophages |
Preparation Method | Mouse J774 macrophages were cultured in DMEM medium supplemented with 2000µM glutamine, 25000µM HEPES, 100U/mL penicillin, 100µg/mL streptomycin, 10% FBS, and 1.2% sodium pyruvate. Cells were seeded in 24-well culture plates at a density of 2.5×105 cells/mL and incubated in a 5% CO2 incubator at 37°C for 2 hours in adherent culture. Cells were stimulated with LPS (10µg/mL) for 24h in the presence or absence of Zileuton (0, 1, 3.3, 10, 33, and 100µM), PGE2 levels were measured in cell supernatants. |
Reaction Conditions | 0, 1, 3.3, 10, 33, and 100µM; 24h |
Applications | Zileuton significantly inhibited the PGE2 generation induced by LPS within J774 macrophages in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | C57BL/B6 APCΔ468 mice |
Preparation Method | Four-week-old C57BL/B6 APCΔ468 mice were housed under standard conditions and fed AIN93G diet with or without 1200mg/kg daily Zileuton homogeneous particles (8 mice per group) for 3 months, and mice were sacrificed at 4 months of age and intestinal tissues were collected for analysis. |
Dosage form | 1200mg/kg/day for 3 months; p.o. |
Applications | Zileuton treatment significantly inhibited intestinal polyp development and inflammation in mice. |
References: | |
| Cas No. | 111406-87-2 | SDF | |
| 别名 | 齐留通; A 64077; Abbott 64077 | ||
| 化学名 | 1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea | ||
| Canonical SMILES | CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O | ||
| 分子式 | C11H12N2O2S | 分子量 | 236.29 |
| 溶解度 | ≥ 13.3mg/mL in DMSO, ≥ 12.73 mg/mL in EtOH | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.2321 mL | 21.1604 mL | 42.3209 mL |
| 5 mM | 0.8464 mL | 4.2321 mL | 8.4642 mL |
| 10 mM | 0.4232 mL | 2.116 mL | 4.2321 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet